Ab Source Biologics Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 08-01-2025
- Paid Up Capital ₹ 1.56 Cr
as on 08-01-2025
- Company Age 10 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 Cr
as on 08-01-2025
- Satisfied Charges ₹ 5.00 M
as on 08-01-2025
- Revenue 197.38%
(FY 2022)
- Profit 73.97%
(FY 2022)
- Ebitda 130.15%
(FY 2022)
- Net Worth -5.63%
(FY 2022)
- Total Assets -8.83%
(FY 2022)
About Ab Source Biologics
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.56 Cr.
The company currently has active open charges totaling ₹2.00 Cr. The company has closed loans amounting to ₹5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Jagannath Sonavane and Mukesh Vinze serve as directors at the Company.
- CIN/LLPIN
U74900PN2014PTC152998
- Company No.
152998
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Nov 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ab Source Biologics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jagannath Sonavane  | Director | 05-Nov-2014 | Current |
| Mukesh Vinze | Director | 05-Nov-2014 | Current |
Financial Performance of Ab Source Biologics.
Ab Source Biologics Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 197.38% increase. The company also saw a substantial improvement in profitability, with a 73.97% increase in profit. The company's net worth dipped by a decrease of 5.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ab Source Biologics?
In 2022, Ab Source Biologics had a promoter holding of 40.00% and a public holding of 60.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Biosphere Life Sciences Private LimitedActive 14 years 2 monthsJagannath Sonavane is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 05 Sep 2016 | ₹2.00 Cr | Open |
Axis Bank Limited Creation Date: 09 Dec 2015 | ₹5.00 M | Satisfied |
How Many Employees Work at Ab Source Biologics?
Ab Source Biologics has a workforce of 26 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ab Source Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ab Source Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
